Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

pNGVL3-hICD vaccine AST-301

A plasmid DNA therapeutic cancer vaccine encoding the intracellular domain (ICD) of the HER-2/neu proto-oncogene, with potential immunomodulating and antineoplastic activities. Upon administration, the pNGVL3-hICD vaccine AST-301 expresses the HER-2/neu protein and elicits a HER-2-specific cytotoxic T-lymphocyte (CTL) immune response against tumor cells expressing HER-2. The HER-2/neu ICD protein is highly immunogenic and, as a subdominant epitope, may be associated with decreased immune tolerance.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:HER-2/neu ICD therapeutic cancer vaccine AST-301
plasmid DNA-based vaccine expressing HER2/neu ICD AST-301
pNGVL3-hICD plasmid DNA-based vaccine AST-301
therapeutic cancer vaccine AST-301
Code name:AST 301
AST-301
AST301
EP 301
EP301
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search